Journal of the American Chemical Society
Article
R. J. Org. Chem. 1993, 58, 3600−3601. (c) Sekar, G.; Nishiyama, H. J.
Am. Chem. Soc. 2001, 123, 3603−3604. (d) Formaggio, F.; Bonchio,
M.; Crisma, M.; Peggion, C.; Mezzato, S.; Polese, A.; Barazza, A.;
Antonello, S.; Maran, F.; Broxterman, Q. B.; Kaptein, B.; Kamphuis, J.;
Vitale, R. M.; Saviano, M.; Benedetti, E.; Toniolo, C. Chem.Eur. J.
2002, 8, 84−93. (e) Graetz, B.; Rychnovsky, S. D.; Leu, W. H.;
Farmer, P.; Lin, R. Tetrahedron: Asymmetry 2005, 16, 3584−3598.
(f) Maayan, G.; Ward, M. D.; Kirshenbaum, K. Proc. Natl. Acad. Sci. U.
of the halogen atom is underway and the results will be reported in
due course.
S. A. 2009, 106, 13679−13684. (g) Muller, C. E.; Hrdina, R.; Wende,
̈
R. C.; Schreiner, P. R. Chem.Eur. J. 2011, 17, 6309−6314.
(15) (a) Adam, W.; Saha-Moller, C. R.; Zhao, C. G. Tetrahedron:
̈
Asymmetry 1998, 9, 4117−4122. (b) Kashiwagi, Y.; Kurashima, F.;
Chiba, S.; Anzai, J.; Osa, T.; Bobbitt, J. M. Chem. Commun. 2003,
114−115. (c) Rong, Z. Q.; Pan, H. J.; Yan, H. L.; Zhao, Y. Org. Lett.
́ ́
2014, 16, 208−211. (d) Carbo Lopez, M.; Royal, G.; Philouze, C.;
Chavant, P. Y.; Blandin, V. Eur. J. Org. Chem. 2014, 2014, 4884−4896.
(16) (a) Tomizawa, M.; Shibuya, M.; Iwabuchi, Y. Org. Lett. 2009,
11, 1829−1831. (b) Correction: Tomizawa, M.; Shibuya, M.;
Iwabuchi, Y. Org. Lett. 2014, 16, 4968−4968.
(33) (a) Whitesell, J. K. Chem. Rev. 1992, 92, 953−964. (b) Comins,
D. L.; Salvador, J. M. Tetrahedron Lett. 1993, 34, 801−804. (c) Sakai,
K.; Suemune, H. Tetrahedron: Asymmetry 1993, 4, 2109−2118.
(34) (a) Oefner, C.; Binggeli, A.; Breu, V.; Bur, D.; Clozel, J. P.;
(17) Sasano, Y.; Murakami, K.; Nishiyama, T.; Kwon, E.; Iwabuchi, Y.
Angew. Chem., Int. Ed. 2013, 52, 12624−12627.
(18) (a) Shibuya, M.; Tomizawa, M.; Suzuki, I.; Iwabuchi, Y. J. Am.
Chem. Soc. 2006, 128, 8412−8413. (b) Shibuya, M.; Sasano, Y.;
Tomizawa, M.; Hamada, T.; Kozawa, M.; Nagahama, N.; Iwabuchi, Y.
Synthesis 2011, 3418−3425. (c) Iwabuchi, Y. Chem. Pharm. Bull. 2013,
61, 1197−1213.
D’Arcy, A.; Dorn, A.; Fischli, W.; Gruninger, F.; Guller, R.; Hirth, G.;
̈
̈
Marki, H. P.; Mathews, S.; Muller, M.; Ridley, R. G.; Stadler, H.;
̈
̈
Vieira, E.; Wilhelm, M.; Winkler, F. K.; Wostl, W. Chem. Biol. 1999, 6,
127−131. (b) Vieira, E.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.;
Guller, R.; Hirth, G.; Marki, H. P.; Muller, M.; Oefner, C.; Scalone, M.;
Stadler, H.; Wilhelm, M.; Wostl, W. Bioorg. Med. Chem. Lett. 1999, 9,
1397−1402. (c) Guller, R.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.;
Hirth, G.; Jenny, C.; Kansy, M.; Montavon, F.; Muller, M.; Oefner, C.;
Stadler, H.; Vieira, E.; Wilhelm, M.; Wostl, W.; Marki, H. P. Bioorg.
Med. Chem. Lett. 1999, 9, 1403−1408.
(35) Marki, H. P.; Binggeli, A.; Bittner, B.; Bohner-Lang, V.; Breu, V.;
̈
̈
̈
́
(19) Semmelhack, M. F.; Schmid, C. R.; Cortes, D. A. Tetrahedron
Lett. 1986, 27, 1119−1122.
̈
(20) Bailey, W. F.; Bobbitt, J. M.; Wiberg, K. B. J. Org. Chem. 2007,
72, 4504−4509.
̈
̈
(21) For reviews of cation−π interaction, see the following: (a) Ma, J.
C.; Dougherty, D. A. Chem. Rev. 1997, 97, 1303−1324. (b) Yamada,
S.; Fossey, J. S. Org. Biomol. Chem. 2011, 9, 7275−7281.
(c) Dougherty, D. A. Acc. Chem. Res. 2013, 46, 885−893.
(22) For an example of diastereoselective nucleophilic addition to 4-
substituted adamantan-2-ones, see the following: Barboni, L.; Filippi,
A.; Fraschetti, C.; Giuli, S.; Marcolini, M.; Marcantoni, E. Tetrahedron
Lett. 2008, 49, 6065−6067.
̈
Bur, D.; Coassolo, P.; Clozel, J. P.; D’Arcy, A.; Doebeli, H.; Fischli, W.;
Funk, C.; Foricher, J.; Giller, T.; Gruninger, F.; Guenzi, A.; Guller, R.;
̈
̈
Hartung, T.; Hirth, G.; Jenny, C.; Kansy, M.; Klinkhammer, U.; Lave,
T.; Lohri, B.; Luft, F. C.; Mervaala, E. M.; Muller, D. N.; Muller, M.;
̈
̈
Montavon, F.; Oefner, C.; Qiu, C.; Reichel, A.; Sanwald-Ducray, P.;
Scalone, M.; Schleimer, M.; Schmid, R.; Stadler, H.; Treiber, A.;
Valdenaire, O.; Vieira, E.; Waldmeier, P.; Wiegand-Chou, R.; Wilhelm,
M.; Wostl, W.; Zell, M.; Zell, R. Farmaco 2001, 56, 21−27.
(36) (a) Kasani, A.; Subedi, R.; Stier, M.; Holsworth, D. D.; Maiti, S.
N. Heterocycles 2007, 73, 47−85. (b) Webb, R. L.; Schiering, N.;
Sedrani, R.; Maibaum, J. J. Med. Chem. 2010, 53, 7490−7520.
(37) (a) Harrison, T.; Williams, B. J.; Swain, C. J.; Ball, R. G. Bioorg.
Med. Chem. Lett. 1994, 4, 2545−2550. (b) Baker, R. H., T.; Swain, C.
J.; Williams, B. J. Patent EP0528495 A1, 1993.
(23) Shibuya, M.; Taniguchi, T.; Takahashi, M.; Ogasawara, K.
Tetrahedron Lett. 2002, 43, 4145−4147.
(24) (a) Imamoto, T.; Sugiura, Y.; Takiyama, N. Tetrahedron Lett.
1984, 25, 4233−4236. (b) Takeda, N. I. T. Org. Synth. 1999, 76, 228.
(25) Camps, P.; El Achab, R.; Font-Bardia, M.; Gorbig, D.; Morral, J.;
̈
Munoz-Torrero, D.; Solans, X.; Simon, M. Tetrahedron 1996, 52,
5867−5880.
̃
(26) See the Supporting Information for synthetic procedures of the
alkoxyamines 5−10.
(38) Lin, P.; Chang, L.; DeVita, R. J.; Young, J. R.; Eid, R.; Tong, X.;
Zheng, S.; Ball, R. G.; Tsou, N. N.; Chicchi, G. G.; Kurtz, M. M.; Tsao,
K. L. C.; Wheeldon, A.; Carlson, E. J.; Eng, W.; Burns, H. D.;
Hargreaves, R. J.; Mills, S. G. Bioorg. Med. Chem. Lett. 2007, 17, 5191−
5198.
(39) For examples of biologically active natural products containing
aryl-substituted piperidinols, see the following: (a) Ismail, I. S.;
Nagakura, Y.; Hirasawa, Y.; Hosoya, T.; Lazim, M. I. M.; Lajis, N. H.;
Shiro, M.; Morita, H. J. Nat. Prod. 2009, 72, 1879−1883. (b) Lazim,
M. I. M.; Ismail, I. S.; Shaari, K.; Abd Latip, J.; Al-Mekhlafi, N. A.;
Morita, H. Chem. Biodiversity 2013, 10, 1589−1596. (c) Morita, H.;
Nugroho, A. E.; Nagakura, Y.; Hirasawa, Y.; Yoshida, H.; Kaneda, T.;
Shirota, O.; Ismail, I. S. Bioorg. Med. Chem. Lett. 2014, 24, 2437−2439.
(40) Herdeis, C.; Kaschinski, C.; Karla, R.; Lotter, H. Tetrahedron:
Asymmetry 1996, 7, 867−884.
(27) For details of the krel value, see ref 2a.
(28) For reports of alcohol oxidation by TEMPO and TCCA, see the
following: (a) De Luca, L.; Giacomelli, G.; Porcheddu, A. Org. Lett.
2001, 3, 3041−3043. (b) De Luca, L.; Giacomelli, G.; Masala, S.;
Porcheddu, A. J. Org. Chem. 2003, 68, 4999−5001.
(29) See the Supporting Information for optimization of the reaction
conditions.
(30) (a) Mei, Z.-W.; Omote, T.; Mansour, M.; Kawafuchi, H.;
Takaguchi, Y.; Jutand, A.; Tsuboi, S.; Inokuchi, T. Tetrahedron 2008,
64, 10761−10766. (b) Hamada, S.; Furuta, T.; Wada, Y.; Kawabata, T.
Angew. Chem., Int. Ed. 2013, 52, 8093−8097.
(31) For a discussion of the effects of halogen atoms on AZADO-
type catalyst under acidic oxidation conditions, see the following:
Shibuya, M.; Nagasawa, S.; Osada, Y.; Iwabuchi, Y. J. Org. Chem. 2014,
79, 10256−10268.
(32) During the review process, a reviewer suggested that Br+ sources
would provide higher enantioselectivity than Cl+ sources owing to the
larger steric effect of a bromine atom than of a chlorine atom. In
accordance with the suggestion, we examined dibromoisocyanuric acid
with the precatalyst 1 for the OKR of racemic secondary alcohols and
found that the 1/dibromoisocyanuric acid system showed a slightly
higher enantioselectivity than TCCA. Further study to clarify the effect
J
dx.doi.org/10.1021/ja509766f | J. Am. Chem. Soc. XXXX, XXX, XXX−XXX